Study record at a glance
| Study ID | NCT07226570 |
|---|---|
| Design | Prospective observational cohort with MRI, MRS, EEG, and qualitative and self-report assessments |
| Condition / topic | Opioid use disorder |
| Population | Adults aged 21 to 65 with opioid use disorder who independently receive ibogaine at a licensed clinic outside the United States; UC Irvine does not provide the treatment |
| Sample size | 20 participants, estimated enrollment |
| Comparator | No comparator group is registered; this is a single observational cohort |
| Follow-up | Imaging and EEG follow-up approximately 4 to 6 weeks after baseline; registered withdrawal and craving measures extend to end of study at 8.5 months |
| Outcome focus | Changes in reward-circuit functional connectivity, drug-cue BOLD activation, regional glutamate and glutamine, EEG alpha power, opioid withdrawal, and craving |
What it suggests
The registered assessments can characterize neural and self-reported changes before and after independently obtained ibogaine treatment in a defined OUD cohort
What it cannot establish
Without randomization or a comparator, the study cannot establish that ibogaine caused an observed change or establish comparative efficacy. The registry record is a protocol, not a result
Recruitment relevance
ClinicalTrials.gov lists the study as recruiting, with registry status verified May 2026. Confirm current openings and eligibility directly with the study team before making travel plans
Do not travel, discontinue medication, or change care based on this summary. The sponsor and the current primary source govern participation decisions.
How this summary was framed
This record reports the design and registered or officially announced research question before interpretation. Unknown sample, comparator, follow-up, and outcome details remain marked as unknown. The Atlas does not infer results from recruitment status, regulatory acceptance, funding, or study completion.